Description
Created On: 2020-07-15
Record Count: 4
Primary Industries
- Drugs
- Therapeutic
- Disease
- Diagnostic
- Drug Discovery
- Proteins
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245952
The Licensor and the Japanese Licensee wish to develop and market novel therapeutic products based on compounds identified pursuant to the Collaboration Agreement. The amendment clarifies, Licensor will screen compounds to identify specific compounds having promising activity for lowering serum LDL-cholesterol through the regulation of CYP7 gene expression or through interaction with the nuclear hormone receptor LXRa.
In the License agreement, Licensor grants the Japanese Licensee the right and license, with the right to sublicense, to develop Preclinical Candidates and to make, have made, use and sell Products under the Licensor Technology and the Licensor-owned and jointly owned Program Technology. The license granted herein shall be exclusive, even as to Licensor, throughout the Licensees Territory.
Product shall mean any pharmaceutical product, including all formulations, line extensions or modes of administration thereof, for use within the Field, which contains an active ingredient which is or is derived from a Preclinical Candidate to this Agreement.
IPSCIO Record ID: 240609
Licensed Compound shall mean a compound which is an Active Compound and which is recommended by the Research Committee and selected by Licensee for GLP Toxicology Studies and further development under the License Agreement.
Active Compound shall mean each Licensee or Licensor Substance which meets the criteria set forth (including any such Substance which was screened in Assays prior to the Effective Date and for which the Research Committee determines that such criteria are met), and each derivative or analogue thereof developed in the course of, but not after, the Research Program or the Tail End Period, if such derivative or analog thereof meets the criteria set forth.
The collaboration agreement is to discover and develop antibacterial drugs based on the two principal targets in the Licensor's anti-bacterial program.
IPSCIO Record ID: 211864
GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.
GEMS-UTR (Gene Expression Modulation by Small-Molecules Untranslated Region) is a proprietary screening technology for the identification of small molecules that modulate gene expression by targeting the post-transcriptional control processes that act through the UTRs of mRNA molecules.
The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient. The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.
This agreement pertains to drug discovery.
IPSCIO Record ID: 249719
This agreement includes non-exclusive terms as well.
(a) the Ne0Morph Screening Library,
(b) the NeoMorph Focused Libraries,
(c) ALIS and QSCD,
(d) the Candidate Compound A,
(e) the Candidate Compound B,
(d) the Candidate Compound C, together with, where applicable, any analogs, derivatives, fragments, sub-cellular constituents or expression products thereof and
(e) any other tangible materials provided by Licensor to Licensee for use in the conduct of the Program, which is Controlled by Licensor, primarily relates to a Designated Compound or Licensed Products, whether or not patentable.
NeoMorph Chemistry means the process, proprietary to Licensor, of forming libraries and sub-libraries of discrete compounds by coupling a broad set of diverse cores with diverse sets of building blocks employing proprietary mass-coding algorithms.
NeoMorph Focused Libraries means those compounds synthesized by Licensor derived from Active Compounds identified by Licensee in bioassays or functional assays NeoMorph Screening Library means the entire collection of libraries consisting of mass-encoded small molecule organic compounds owned by Licensor and developed with NeoMorph Chemistry, comprising at least 10,000,000 different compounds.
Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets. Licensor has certain technology and know-how, including screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.
The Field means treatment of any disease in humans.
